| Literature DB >> 32911777 |
Kun-Che Chang1,2, Yu-Kai Huang3,4,5, Yen-Wen Chen6,7, Min-Hui Chen8, Anthony T Tu9, Yen-Chia Chen10,11,12.
Abstract
Little is known about the detailed clinical description, pathophysiology, and efficacy of treatments for ocular envenoming (venom ophthalmia) caused by venom of the spitting elapid and other snakes, as well as ocular complications caused by snake venom injection. In this paper, we review clinical information of case reports regarding venom ophthalmia and snake venom injection with associated ocular injuries in Asia, Africa, and the United States. We also review the literature of snake venom such as their compositions, properties, and toxic effects. Based on the available clinical information and animal studies, we further discuss possible mechanisms of venom ophthalmia derived from two different routes (Duvernoy's gland in the mouth and nuchal gland in the dorsal neck) and the pathophysiology of snake venom injection induced ocular complications, including corneal edema, corneal erosion, cataract, ocular inflammation, retinal hemorrhage, acute angle closure glaucoma, as well as ptosis, diplopia, and photophobia. Finally, we discuss the appropriate first aid and novel strategies for treating venom ophthalmia and snake envenoming.Entities:
Keywords: corneal edema; nuchal gland; retinal hemorrhage; snake venom; snakebite; spitting venom
Mesh:
Substances:
Year: 2020 PMID: 32911777 PMCID: PMC7551025 DOI: 10.3390/toxins12090576
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Snake venom ophthalmia via venom spray (A) and venom injection (B).
Figure 2Duvernoy’s gland (A) and nuchal gland (B) are two different systems of venom spray.
Venom ophthalmia caused by venomous snakes.
| Species | Family | Gland | Venom Components | Spitting Distance (Meter) | Ocular Lesions | Treatments | Outcome | Ref. |
|---|---|---|---|---|---|---|---|---|
|
|
| Duvernoy | α-Neurotoxin PLA2
| 0.7–1 | Conjunctivitis; corneal injury; Keratoconjunctivitis; Keratitis; Photophobia | Water irrigations; topical antibiotics, corticosteroids, and vasoconstrictors; Analgesics | Full recovery | [ |
|
|
| Duvernoy | α-Neurotoxin PLA2
| 0.2 | conjunctival inflammation and swelling of the eyelids | Water irrigations | Full recovery | [ |
|
|
| Duvernoy | α-Neurotoxin PLA2
| 0.8–2 | Corneal injury; hypopyon; uveitis; conjunctival hyperemia | Water irrigations; topical antibiotics, corticosteroids atropine; Analgesics | Recovered with sequelae; | [ |
|
|
| Duvernoy | α-Neurotoxin PLA2
| 0.5–1 | Blepharitis, blepharospasm, conjunctivitis | Water irrigations | Full recovery | [ |
|
|
| Duvernoy | α-Neurotoxin PLA2
| 2 | Conjunctivitis | Water irrigations; Epinephrine | Full recovery | [ |
|
|
| Duvernoy | PLA2
| 1 | Red eye | Water irrigations | Full recovery | [ |
|
|
| Duvernoy | PLA2
| n/a | Photophobia | Water irrigations; Topical antivenom, Analgesics | Full recovery | [ |
|
|
| Nuchal | bufadienolides | n/a | Conjunctivitis, keratitis, corneal clouding | Saline irrigations; topical antibiotics, corticosteroids | Full recovery | [ |
|
|
| Nuchal | bufadienolides | 1 | Keratitis, corneal stromal edema and conjunctival congestion | Water irrigation; topical corticosteroid, antihistamine and antibiotic | Full recovery | [ |
PLA2: Phospholipases A2; LAAO: L-amino acid oxidases; CTXs: Cardiotoxins; SVMPs: Snake venom metalloproteinases.
Ocular complications following snake venom injection.
| Species | Sex/Age | Other Symptoms | Presuming Venom | * Possible Direct Mechanism | Antivenom/ | Outcome | Ref. | |
|---|---|---|---|---|---|---|---|---|
| Anterior segment manifestations | ||||||||
| Subconjunctival hemorrhage | Unknown | M/70 | Acute renal failure | SVMPs | * Proteolytic effect | IV Antivenom/ 16 vials | Recovery | [ |
| Corneal striae, anterior | Unknown | M/70 | Acute renal failure | Hemotoxin | # Secondary of subconjunctival hemorrhage and side effect of antivenom | IV Antivenom/ 16 vials | Remain corneal striae and cataract | [ |
| Cataract | Unknown | M/60 | AMS | SVMPs | # Anterior inflammation caused by vitreous hemorrhage | IV Antivenom/ Unclear | NLP | [ |
| Iris atrophy, Cataract | Unknown | M/55 | Anasarca | Cytotoxin | * Anterior ischemia | IV Antivenom/ Unclear | IMC | [ |
| Iris atrophy, Cataract | Unknown | M/45 | Limb edema | Cytotoxin | * Anterior ischemia | IV Antivenom/ Unclear | Lost for follow-up | [ |
| Posterior segment manifestations | ||||||||
| CRAO | Unknown | M/26 | Headache | Hemotoxin | * Coagulopathy | Unclear | Reduction of vision | [ |
| CRAO | Unknown | M/24 | Bleeding diathesis | Hemotoxin | * Coagulopathy | As above | Reduction of vision | [ |
| CRAO | Viper | F/30 | AMS | Hemotoxin, | * Coagulopathy | IV Antivenom/ Unclear | Poor visual prognosis | [ |
| CRAO | Viper | F/17 | n/a | Hemotoxin | * Coagulopathy | IV Antivenom/ Unclear | Lost for follow-up | [ |
| Retinal or vitreous hemorrhage | Viper | F/17 | AMS | SVMPs | * Proteolytic effect | IV Antivenom/ Unclear | NLP | [ |
| Vitreous hemorrhage | Viper | M/60 | AMS | SVMPs | * Proteolytic effect | IV Antivenom/ Unclear | 20/200 for O.U. | [ |
| Macular infarction | Viper | F/17 | AMS | Hemotoxin | * Thrombosis | IV Antivenom/ Unclear | NLP | [ |
| Retinal detachment | Unknown | F/13 | Vitreous hemorrhage | SVMPs | * Hemorrhage-induced subretinal edema | IV Antivenom/ | 20/200 for O.S. Reduction of vision for O.D. | [ |
| Glaucoma | ||||||||
| AACG | Unknown | M/70 | Acute renal failure | Hemotoxin | # Capillary leak due to hematoxin | IV Antivenom/ 16 vials | Lost for follow-up | [ |
| AACG |
| F/67 | AMS | Hemotoxin, Neurotoxin | * Coagulation cascade and synapse disorder | IV Antivenom/ Unclear | BCVA is 5/10 for O.S. | [ |
AMS: Altered mental status; SVMPs: Snake venom metalloproteinases; NLP: No light perception; IMC: Immature cataract; BCVA: Best corrected visual acuity.